INTRODUCTION The purpose of this study was to document the efficacy and tolerability of the new fixed-combination (FC) brinzolamide 1%/timolol 0.5% as used in daily practice throughout Germany. METHODS An open-label, multicenter, observational study of patients was performed that evaluated the transition from prior medication to brinzolamide/timolol FC for the reduction of intraocular pressur...

A sensitive and fast UV spectrophotometric technique and feasible reverse phase liquid chromatographic method for the analysis of Brinzolamide and Brimonidine tartrate in ophthalmic formulation has been developed. Linearity ranges for both methods were 5 25 ìg/ml and 1-5 ìg/ml for brinzolamide and brimonidine tartrate respectively. The absorption maxima were observed at 232 and 257 nm for Brinz...

Brinzolamide 1%/timolol 0.5% is a new fixed-combination for the treatment of open-angle glaucoma or ocular hypertension. Brinzolamide/timolol has a favorable safety profile, with an incidence of ocular burning and stinging <5%. Published data show that brinzolamide 1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% have similar efficacies for lowering intraocular pressure (IOP). There is some evid...

PURPOSE To investigate the efficacy of dorzolamide 1% (bid or tid) or brinzolamide 1% bid on 24-hour intraocular pressure (IOP) control as well as patients' preference for either drug when added in combination with latanoprost against glaucoma (IOP, >/=18 mmHg). METHODS In this randomized crossover study patients were assigned to receive latanoprost plus either dorzolamide or brinzolamide for...

OBJECTIVE To assess ocular discomfort upon instillation and patient preference for brinzolamide/timolol relative to dorzolamide/timolol, in patients with open-angle glaucoma or ocular hypertension. METHODS This was a multicenter, prospective, patient-masked, randomized, crossover study. On day 0, patients received one drop of brinzolamide/timolol in one eye and one drop of dorzolamide/timolol...

To investigate the effect of brinzolamide on diurnal fluctuations in the intraocular pressure (IOP) in patients on latanoprost ophthalmic solution prospectively was aimed. Eleven patients with primary open angle glaucoma were enrolled in this study. The subjects were admitted to the hospital and had their IOPs measured over 24 hours (10 AM, noon, 2 PM, 4 PM, 6 PM, 8 PM, 10 PM, midnight, 3 AM, 6...

PURPOSE To determine patient preference of and ocular discomfort with fixed combination brinzolamide/timolol compared with fixed combination dorzolamide/timolol. METHODS In a prospective, double-masked, randomized, active-controlled, crossover, multicenter study, patients received 1 drop of brinzolamide/timolol and dorzolamide/timolol in both eyes on consecutive days in random order. Ocular d...

PURPOSE To study the effect of the concomitant use of brinzolamide and latanoprost on the 24-hour variation in intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients first treated with timolol and latanoprost. METHODS We studied 30 eyes from 30 POAG patients previously treated with latanoprost monotherapy. After a washout of four weeks in both eyes, all patients were treate...

Brinzolamide is a white powder commercially formulated as a 1% ophthalmic suspension to reduce intraocular pressure (IOP). Pharmacologically, brinzolamide is a highly specific, non-competitive, reversible, and effective inhibitor of carbonic anhydrase II (CA-II), able to suppress formation of aqueous humor in the eye and thus to decrease IOP. Several clinical trials have evaluated its safety an...

PURPOSE To compare the diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure (IOP) in patients already receiving monotherapy with latanoprost. DESIGN Prospective, open-label, and crossover clinical trial. PARTICIPANTS Twenty-six patients with glaucoma or ocular hypertension (ages, 44-79 years) who were receiving treatment with 0.005% latanoprost once every evenin...